November 9–11, 2026 | Cologne, Germany
MindRank, a China-based industry leader in AI-native pharmacy discovery and development, will be at BIO-Europe 2026 in Cologne.
Attend us at BIO-Europe 2026 to connect with our team and discuss our metabolic and oncology assets, intera life-science foundation model system and potential collaborations.
Our pipeline highlights
MDR-001 | Small-molecule Oral GLP-1 receptor agonist
MDR-001, an AI-designed oral small-molecule GLP-1 receptor agonist, is in Phase III clinical development in China.
MindRank has entered into an exclusive commercialization agreement for MDR-001 with 3SBio (01530.HK), covering mainland China, Hong Kong and Macau.
The agreement has a potential total transaction value of up to $260 million, subject to agreed conditions, plus a substantial share of sales revenue for MindRank.
MRANK-106 | Dual WEE1/YES1 inhibitor
A potential first-in-class candidate targeting DNA damage response checkpoints and related signaling pathways. Preclinical studies indicate that MRANK-106 has low hematotoxicity. Development focuses include pancreatic and esophageal cancers and hematologic malignancies with elevated expression of the relevant targets. MRANK-106 has received IND clearance from both China’s NMPA and the U.S. FDA.
MRANK-111 | Oral CB1-targeting obesity candidate
A next-generation oral small molecule designed for use alone or alongside GLP-1 therapies. BBB penetration is low. Preclinical studies have shown weight-loss activity as monotherapy and in combination with GLP-1 therapies. The program is in IND-enabling development.
MRANK-101 | P53-targeted oncology candidate
A potent, highly bioavailable oral small-molecule TP53 inhibitor with the potential for once-daily oral dosing, currently at the preclinical candidate (PCC) stage. Target indications include non-small cell lung, breast, colorectal, gastric and pancreatic cancers. The candidate has best-in-class potential.
Intera | Life-sciences foundation models
Intera, our AI-driven life-sciences foundation model system, is designed to support research into disease, mechanism, medicine and patient questions.
We published a technical report for the first model in its InteraFold series, InteraFold-Chem on predicting how small molecules bind to proteins, providing structural insights for experimental follow-up.
Within this framework, InteraFold focuses on how different therapeutic modalities bind to their targets, with the newly released InteraFold-Chem dedicated to small molecules. Planned models include InteraDesign for molecular generation and design, and InteraBio for advancing biological understanding.
Alongside Intera, our proprietary AI-driven Molecule Arts Platform (MAP) integrates biology, chemistry, computation, experimental evidence and clinical learning across new drug R&D.
Schedule a meeting through partneringONE: search for “MindRank” and send us a meeting request, or email bd@mindrank.ai.
See you in Cologne!
#BIOEurop